Colchicine could be considered as a treatment for non-hospitalized patients diagnosed with COVID-19 by PCR test and at risk of complicationsMONTREAL, May 28, 2021 (GLOBE NEWSWIRE) The Montreal Heart
Article content
MONTREAL, March 16, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announces that the BRAIN-AF study has received a $1.4 million grant from the Canadian Institutes of Health Research. Seeking to better understand the effects of cardiovascular disease on the cognitive decline of the brain, the study will be able to recruit participants remotely thanks to this funding.
BRAIN-AF is studying a common heart rhythm disorder called atrial fibrillation (AF). This is the first study in the world to analyze the effects of atrial fibrillation on cognitive decline in young patients up to age 65. “We hypothesize that cardiac microclots damage the brains of young patients with atrial fibrillation,” says Dr. Lena Rivard, a cardiologist specializing in electrophysiology at the MHI, and the principal investigator of the BRAIN-AF study launched in 2015 with her colleagues, Drs. Denis Roy and Paul Khairy.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Colchicine reduces the risk of COVID-19-related complications
Montreal Heart InstituteJanuary 23, 2021 GMT
MONTREAL, Jan. 22, 2021 (GLOBE NEWSWIRE) The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo. This result obtained for the global study population of 4488 patients approached statistical significance. The analysis of the 4159 patients in whom the diagnosis of COVID-19 was proven by a naso-pharyngeal PCR test has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo. In these patients with a proven diagnosis of COVID-19, c